Vertex Pharmaceuticals Incorporated (VRTX) exhibits 86.2% gross margins and 20.0% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 29.6x enterprise multiple and 4.8% implied options volatility.
Sustained 86.2% gross profitability converts into 34.8% operating margin and 20.0% ROIC, outpacing sector cost of capital.
ROIC: 20.0% // GM: 86.2%YoY revenue trajectory of +8.9% paired with 2.33% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +8.9% // FCF YLD: 2.33%Altman Z-Score of 13.86 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 13.86 // F-SCORE: 8/9Trading at 34.6x trailing P/E (32.2x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 34.6x // EV/EBITDA: 29.6xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $558.88 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 32.9% net margins.
NET MARGIN: 32.9% // D/E: 0.16x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for VRTX & activate live FRED threshold breach alerts.